Yonsei, REPUBLIC OF KOREA - 30 Aug `18Investigation on the Expression of HMGB1

Official Title: The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity

In Brief: Vitiligo is an acquired depigmented disorder that causes white spots on the skin due to the loss of melanocytes. It is a common disease which accounts for 0.5-1% of the whole population. It is a refractory skin disease with 25-50 thousand patients in Korea. And it is often caused in the exposed areas of the patient, causing a great deal of mental and social dysfunction in the patient's life, and may lead to suicide attempts.

Ages Eligible: 19 Years and older

Start Date: August 30, 2018

Completion Date (estimated): August 29, 2020

Status: Active, recruiting

Study ID from ClinicalTrials.gov: NCT03741738

Location: Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea, 03722

Contact: To learn more about this study, you or your doctor may contact Sang Ho Oh, MD, PhD by phone +82 2 2228 2080 or email oddung93@yuhs.ac. Please refer to this study by its NCT number.

FAQOther Questions

  • Shall I take vitamin D for my vitiligo?

    In Brief Vitamin D plays a central role in the prevention of different inflammatory and chronic diseases. Consuming 1,000–4,000 IU (25–100 mcg) of vitamin D3 daily should be id...

  • Is there a special diet for vitiligo?

    In short, no.  Some people find that certain foods may worsen their vitiligo symptoms or that others may improve their skin condition. We found no scientific evidence that a sp...

  • What tests should be done?

    A well-trained dermatologist should be able to diagnose vitiligo and distinguish it from contact leukoderma or more than twenty other conditions with similar skin appearance bas...